Study Name:
A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using Exablate focused ultrasound during the standard of care treatment of brain metastases of non-small cell lung cancer (NSCLC) origin

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The primary objective is to evaluate the safety and efficacy of blood brain barrier disruption using the Exablate Type 2 system in adult subjects with brain metastases of NSCLC origin that are either undergoing or have planned standard of care pembrolizumab monotherapy as compared to subjects that are undergoing standard of care pembrolizumab without Exablate blood brain barrier disruption.
 

Study Dates:
August 12, 2022 - December 30, 2024

Study Location:
Nationwide

Lead Institution:
Miami Cancer Institute, Baptist Health South Florida

Funding Source:
Insightec

ClinicalTrails.gov Identifier:
NCT05317858

Sponsor: 
Insightec

Contact:
Contact Phone: 774-266-6280
Contact Email: [email protected]

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Freedom From Smoking Virtual Clinic
San Jose, CA | Oct 24, 2022